keyword
https://read.qxmd.com/read/38527835/-clinical-analysis-of-14-patients-aged-%C3%A2-50-years-with-high-risk-multiple-myeloma-treated-with-allogeneic-hematopoietic-stem-cell-transplantation
#1
JOURNAL ARTICLE
P Pan, J L Wang, W H Zhai, Q L Ma, D L Yang, S Z Feng, M Z Han, A M Pang, E L Jiang
Objective: To evaluate the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in young patients with high-risk multiple myeloma (HRMM) and analyzed the factors affecting patient prognosis. Methods: In this retrospective study, we analyzed the clinical data of 14 patients with HRMM with cytogenetic abnormalities or high-risk biological factors who underwent allo-HSCT at the Hematopoietic Stem Cell Transplantation Center of the Institute of Hematology & Blood Diseases Hospital between November 2016 and November 2022...
January 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38527834/-clinical-features-and-risk-factors-for-invasive-fungal-sinusitis-after-allogeneic-hematopoietic-stem-cell-transplantation
#2
JOURNAL ARTICLE
H X Fu, J J Li, Y Y Zhang, Y Q Sun, X D Mo, T T Han, J Kong, M Lyu, W Han, H Chen, Y Y Chen, F R Wang, C H Yan, Y Chen, J Z Wang, Y Wang, L P Xu, X J Huang, X H Zhang
Objective: To analyze the clinical characteristics and outcomes of patients with invasive fungal sinusitis (invasive fungal rhinosinusitis, IFR) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and explored the risk factors for IFR after allo-HSCT. Methods: Nineteen patients with IFR after allo-HSCT at Peking University People's Hospital from January 2012 to December 2021 were selected as the study group, and 95 patients without IFR after allo-HSCT during this period were randomly selected as the control group (1:5 ratio) ...
January 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38522856/severe-liver-dysfunction-after-donor-lymphocyte-infusion-for-relapsed-multiple-myeloma
#3
Tae-Hoon No, Nae-Yun Heo, Seung Ha Park, Joon Hyuk Choi, Junghwan Lee, Sung Nam Lim, Seon Yang Park
Donor lymphocyte infusion (DLI) is performed to augment an anti-tumor immune response or ensure donor stem cells remain engrafted following allogeneic stem cell transplantation but may induce graft-versus-host disease (GVHD) involving skin, intestine, and liver. Although hepatic involvement of GVHD can manifest as mild to severe hepatitis, few reports have mentioned acute severe liver dysfunction with encephalopathy. We experienced a case of acute severe liver dysfunction with semicoma after DLI in a patient with relapsed multiple myeloma following allogeneic stem cell transplantation, in whom chronic viral hepatitis B had been suppressed by antiviral treatment...
March 25, 2024: Korean Journal of Gastroenterology, Taehan Sohwagi Hakhoe Chi
https://read.qxmd.com/read/38508880/long-term-follow-up-of-the-combination-of-ofatumumab-high-dose-methylprednisolone-and-lenalidomide-for-untreated-chronic-lymphocytic-leukemia-with-biomarker-analysis
#4
JOURNAL ARTICLE
Julio C Chavez, Ariel Grajales, Jose Sandoval-Sus, Elyce Turba, Lisa Nodzon, Angimar Uriepero-Palma, Mohammad Ammad-Ud-Din, Eva Sahakian, Rami Komrokji, Lubomir Sokol, Frederick L Locke, Bijal Shah, Jeffrey Lancet, Eduardo M Sotomayor, Mohamed A Kharfan-Dabaja, Celeste Bello, Javier Pinilla-Ibarz
BACKGROUND: Advancements in frontline therapy and chemotherapy-sparing treatments in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have altered the treatment algorithms of this disease. We present a frontline alternative for treatment- naïve (TN) CLL/SLL patients. METHODS: This was a single-center, phase 2 study of high-dose methylprednisolone (HDMP) and ofatumumab with lenalidomide and ofatumumab consolidative therapy for all comers with TN CLL/SLL...
February 13, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38485650/soho-state-of-the-art-updates-and-next-questions-measurable-residual-disease-in-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia
#5
REVIEW
Nicholas J Short, Elias Jabbour, Hagop Kantarjian
Assessment of measurable residual disease (MRD) provides important prognostic information and can inform decision-making about appropriate consolidative therapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Many contemporary treatment protocols for Ph+ ALL achieve high rates of MRD negativity, and several analyses suggest that allogeneic hematopoietic stem cell transplant in first remission can be safely deferred in most patients who achieve MRD negativity by PCR for BCR::ABL1 within 3 months...
February 21, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38483213/phase-1-study-of-bortezomib-fludarabine-and-melphalan-with-or-without-total-marrow-irradiation-as-allogeneic-hematopoietic-stem-cell-transplant-conditioning-for-high-risk-or-relapsed-refractory-multiple-myeloma
#6
JOURNAL ARTICLE
Colton Ladbury, James Sanchez, Arnab Chowdhury, Joycelynne Palmer, An Liu, Anthony Stein, Myo Htut, Leonardo Farol, Ji-Lian Cai, George Somlo, Michael Rosenzweig, Jeffrey C Wong, Firoozeh Sahebi
OBJECTIVES: We conducted a phase 1 study of a conditioning regimen with or without total marrow irradiation (TMI) before allogeneic hematopoietic stem cell transplantation for patients with high-risk or refractory multiple myeloma. METHODS: Eighteen patients were enrolled on one of 2 strata. Patients with no prior radiation received TMI (900 cGy), fludarabine (FLU), and melphalan (MEL) conditioning, with bortezomib added in the second cohort (stratum I). Patients with prior radiation received FLU, MEL, and bortezomib, without TMI (stratum II)...
March 14, 2024: American Journal of Clinical Oncology
https://read.qxmd.com/read/38466402/long-term-survival-and-functional-outcomes-of-critically-ill-patients-with-hematologic-malignancies-a-canadian-multicenter-prospective-study
#7
JOURNAL ARTICLE
Laveena Munshi, Guillaume Dumas, Bram Rochwerg, Farah Shoukat, Michael Detsky, Dean A Fergusson, Bruno L Ferreyro, Paul Heffernan, Margaret Herridge, Sheldon Magder, Mark Minden, Rakesh Patel, Salman Qureshi, Aaron Schimmer, Santhosh Thyagu, Han Ting Wang, Sangeeta Mehta
PURPOSE: Patients with hematologic malignancy (HM) commonly develop critical illness. Their long-term survival and functional outcomes have not been well described. METHODS: We conducted a prospective, observational study of HM patients admitted to seven Canadian intensive care units (ICUs) (2018-2020). We followed survivors at 7 days, 6 months and 12 months following ICU discharge. The primary outcome was 12-month survival. We evaluated functional outcomes at 6 and 12 months using the functional independent measure (FIM) and short form (SF)-36 as well as variables associated with 12-month survival...
March 11, 2024: Intensive Care Medicine
https://read.qxmd.com/read/38459171/hematopoietic-cell-transplantation-and-cell-therapy-activity-landscape-survey-in-the-kingdom-of-saudi-arabia-a-report-from-the-saudi-society-of-blood-and-marrow-transplantation-ssbmt
#8
JOURNAL ARTICLE
(no author information available yet)
Hematopoietic Cell Transplantation (HCT) activity was surveyed in the Kingdom of Saudi Arabia (KSA). The overall rate of HCT per 10,000,000 inhabitants doubled every 10 years. 15,031 HCTs were reported by all the functional HCT centers in KSA since inception of HCT program. Out of total HCT 15,031; 10,232(68%) were reported in adults, and 4799(32%) in the pediatric population. Allogeneic HCT constituted 10,489(70%) of total HCT, with majority from Human Leukocyte Antigen matched identical sibling (85.4%)...
March 8, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38453275/nation-wide-retrospective-analysis-of-allogeneic-stem-cell-transplantation-in-patients-with-multiple-myeloma-a-study-from-korean-multiple-myeloma-working-party-kmm1913
#9
JOURNAL ARTICLE
Ho-Jin Shin, Do-Young Kim, Kihyun Kim, Chang-Ki Min, Je-Jung Lee, Yeung-Chul Mun, Won-Sik Lee, Sung-Nam Lim, Jin Seok Kim, Joon Ho Moo, Da Jung Kim, Soo-Mee Bang, Jong-Ho Won, Jae-Cheol Jo, Young Il Koh
PURPOSE: The role of allogeneic stem cell transplantation (alloSCT) in multiple myeloma (MM) treatment remains controversial. We conducted a retrospective, multicenter, nationwide study in Korea to evaluate the outcomes of alloSCT in Asian patients with MM. MATERIALS AND METHODS: Overall, 109 patients with MM who underwent alloSCT between 2003 and 2020 were included in this study. Data were collected from the Korean Multiple Myeloma Working Party Registry. RESULTS: The overall response rate and stringent complete response (sCR) plus CR rates were 67...
March 4, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38431521/outcome-of-patients-with-relapsed-acute-promyelocytic-leukemia
#10
JOURNAL ARTICLE
Koji Sasaki, Farhad Ravandi, Tapan Kadia, Courtney D DiNardo, Musa Yilmaz, Nicholas Short, Elias Jabbour, Keyur P Patel, Sanam Loghavi, Sherry Pierce, Gautam Borthakur, Hagop Kantarjian
BACKGROUND: The outcome of patients with acute promyelocytic leukemia (APL) has improved significantly since the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) as APL therapies. The optimal therapy for APL relapse is believed to require autologous or allogeneic stem cell transplantation (SCT) based on historical experience. STUDY AIMS: To evaluate the outcome of patients with relapsed APL before and after the era of ATRA-ATO. PATIENTS AND METHODS: We reviewed 61 patients with relapsed APL treated from November 1991 to June 2023; 31 patients (51%) received modern therapy with the combination of ATRA and ATO with and without idarubicin and gemtuzumab ozogamicin (GO)...
February 3, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38430810/cellular-therapies-in-older-adults-with-hematological-malignancies-a-case-based-state-of-the-art-review
#11
JOURNAL ARTICLE
Nina Rosa Neuendorff, Abdullah Khan, Fabian Ullrich, Samuel Yates, Srinivas Devarakonda, Richard J Lin, Bastian von Tresckow, Raul Cordoba, Andrew Artz, Ashley E Rosko
Cellular therapies, including autologous stem cell transplant (ASCT), allogeneic hematopoietic cell transplantation (alloHCT), and chimeric antigen receptor- (CAR-) T cell therapies are essential treatment modalities for many hematological malignancies. Although their use in older adults has substantially increased within the past decades, cellular therapies represent intensive treatment approaches that exclude a large percentage of older adults due to comorbidities and frailty. Under- and overtreatment in older adults with hematologic malignancy is a challenge and many treatment decisions are influenced by chronologic age...
February 29, 2024: Journal of Geriatric Oncology
https://read.qxmd.com/read/38429222/hypomethylating-agents-and-venetoclax-for-acute-myeloid-leukemia-relapsed-after-hematopoietic-stem-cell-transplant
#12
JOURNAL ARTICLE
Filip Ionescu, Jerel C David, Apoorva Ravichandran, David A Sallman, Kendra Sweet, Rami S Komrokji, Onyee Chan, Andrew Kuykendall, Eric Padron, Rawan Faramand, Nelli Bejanyan, Farhad Khimani, Hany Elmariah, Joseph Pidala, Asmita Mishra, Lia Perez, Taiga Nishihori, Jeffrey E Lancet
BACKGROUND: Hypomethylating agent + venetoclax is an effective frontline combination for acute myeloid leukemia, but its efficacy and safety in post-allogeneic hematopoietic cell transplant (alloHCT) relapse remain underexplored. Outcomes have been poor for this population, with no standard treatment. PATIENTS AND METHODS: We retrospectively analyzed 72 Ven-naïve patients who received hypomethylating agents + venetoclax at relapse following alloHCT and aimed to evaluate the rates of complete remission with or without hematologic recovery (CR/CRi) and minimal residual disease (MRD) negativity, CR/CRi duration, and overall survival...
February 12, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38425944/autologous-gastrointestinal-graft-vs-host-disease-in-a-patient-with-multiple-myeloma-and-hematopoietic-stem-cell-transplantation
#13
Hasan Raza, Sandra Naffouj, Grace Guzman, Asim Shuja
Graft-vs-host disease (GVHD) of the gastrointestinal (GI) tract is notably a serious complication of allogeneic hematopoietic stem cell transplant (HSCT). However, GI GVHD has rarely been reported in autologous HSCT, and the pathophysiology remains unclear. Diagnosing GVHD after autologous HSCT requires a high level of clinical suspicion, given its nonspecific clinical presentation and endoscopic findings necessitating a histological diagnosis for confirmation. We present a case of autologous GVHD involving the GI tract in a patient with multiple myeloma who responded well to corticosteroids, highlighting the importance of early identification of this rare entity to initiate therapy and improve outcomes...
March 2024: ACG Case Reports Journal
https://read.qxmd.com/read/38407192/cytomegalovirus-immunoglobulin-serology-prevalence-in-patients-with-newly-diagnosed-multiple-myeloma-treated-within-the-gmmg-mm5-phase-iii-trial
#14
JOURNAL ARTICLE
Hans Salwender, Niels Weinhold, Axel Benner, Kaya Miah, Maximilian Merz, Mathias Haenel, Christian Jehn, Elias Mai, Ekaterina Menis, Igor Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Steffen Luntz, Britta Besemer, Markus Munder, Peter Brossart, Bertram Glass, Hans-Walter Lindemann, Katja Weisel, Christine Hanoun, Paul Schnitzler, Sarah Klemm, Hartmut Goldschmidt, Marc Raab, Ahmet Elmaagacli
OBJECTIVES: The seroprevalence of antibodies against Cytomegalovirus (CMV) is an established poor prognostic factor for patients receiving an allogeneic stem cell transplantation. However, the impact of CMV serology on outcome after autologous stem cell transplantation remains unknown. METHODS: Here, we analyzed the CMV immunoglobulin (Ig) serology of 446 newly-diagnosed multiple myeloma (MM) patients of the GMMG-MM5 phase III trial with a median follow-up of 58 months...
December 2024: Hematology (Amsterdam, Netherlands)
https://read.qxmd.com/read/38403505/azacitidine-post-transplant-maintenance-improves-disease-progression-in-high-risk-acute-myeloid-leukemia-and-myelodysplastic-syndrome
#15
JOURNAL ARTICLE
Oren Pasvolsky, Rima M Saliba, Uday R Popat, Amin Alousi, Rohtesh Mehta, Jason Yeh, Gheath Al-Atrash, Masood Adeel, Jeremy Ramdial, David Marin, Gabriela Rondon, Partow Kebriaei, Richard Champlin, Naval Daver, Courtney Dinardo, Nicholas J Short, Elizabeth J Shpall, Betül Oran
BACKGROUND: Maintenance after allogeneic hematopoietic cell transplantation (alloHCT) with hypomethylating agents has yielded conflicting results. MATERIALS AND METHODS: We conducted a single center retrospective matched-control analysis with the study group (5-azacitidine [AZA] group) including adults with FLT3-negative acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who received post-transplant AZA maintenance off clinical trial (n = 93). A matched control group was comprised of contemporaneous AML/MDS patients who did not receive any maintenance (n = 357)...
February 3, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38343800/sars-cov-2-vaccination-in-the-first-year-after-hematopoietic-cell-transplant-or-chimeric-antigen-receptor-t-cell-therapy-a-prospective-multicenter-observational-study-bmt-ctn-2101
#16
Joshua A Hill, Michael J Martens, Jo-Anne H Young, Kavita Bhavsar, Jianqun Kou, Min Chen, Lik Wee Lee, Aliyah Baluch, Madhav V Dhodapkar, Ryotaro Nakamura, Kristin Peyton, Dianna S Howard, Uroosa Ibrahim, Zainab Shahid, Paul Armistead, Peter Westervelt, John McCarty, Joseph McGuirk, Mehdi Hamadani, Susan DeWolf, Kinga Hosszu, Elad Sharon, Ashley Spahn, Amir A Toor, Stephanie Waldvogel, Lee M Greenberger, Jeffery J Auletta, Mary M Horowitz, Marcie L Riches, Miguel-Angel Perales
BACKGROUND: The optimal timing of vaccination with SARS-CoV-2 vaccines after cellular therapy is incompletely understood. OBJECTIVE: To describe humoral and cellular responses after SARS-CoV-2 vaccination initiated <4 months versus 4-12 months after cellular therapy. DESIGN: Multicenter prospective observational study. SETTING: 34 centers in the United States. PARTICIPANTS: 466 allogeneic hematopoietic cell transplant (HCT; n=231), autologous HCT (n=170), or chimeric antigen receptor T cell (CAR-T cell) therapy (n=65) recipients enrolled between April 2021 and June 2022...
January 25, 2024: medRxiv
https://read.qxmd.com/read/38267354/soho-state-of-the-art-updates-and-next-questions-ctls-for-infections-following-stem-cell-transplantation
#17
REVIEW
Ariel Rischall, Amanda Olson
Allogeneic hematopoietic stem cell transplantation (AHSCT) is an important modality in the treatment of acute leukemia and other hematologic disorders. The post-transplant period is associated with prolonged periods of impaired immune function. Delayed T-cell immune reconstitution is correlated with increased risk of viral, bacterial, and fungal infections. This risk increases with high intensity inductions regimens often required for alternative donor sources. Current therapies for prophylaxis and treatment of these infections are limited by poor efficacy and significant toxicity...
January 9, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38228094/health-related-complications-during-follow-up-and-their-impact-on-blood-cancer-survivors-results-from-the-aftercare-in-blood-cancer-survivors-abc-study
#18
JOURNAL ARTICLE
Julia Baum, Hildegard Lax, Nils Lehmann, Anja Merkel-Jens, Dietrich W Beelen, Karl-Heinz Jöckel, Ulrich Dührsen
Introduction Blood cancer survivors are at increased risk for medical complications. Methods Our questionnaire-based study involved 1,551 blood cancer survivors with a ≥3-year interval since the last intense treatment. Its goal was to quantify health-related complications during follow-up and assess their impact on the patients' lives. Results 20.4% of responding survivors reported a disease relapse, most often in indolent lymphomas. Second primary malignancies occurred in 14.1%, primarily in lymphoma and allogeneic transplantation survivors...
January 16, 2024: Acta Haematologica
https://read.qxmd.com/read/38197968/comparison-of-antibody-based-immunotherapeutics-for-malignant-hematological-disease-in-an-experimental-murine-model
#19
JOURNAL ARTICLE
Jörn C Albring, Karin Frebel, Anika Wohlgemuth, Christian Schwöppe, Stephan Hailfinger, Georg Lenz, Matthias Stelljes
Antibody-based immunotherapies have revolutionized leukemia and lymphoma treatment, with animal studies being crucial in evaluating effectiveness and side effects. By targeting the evolutionary conserved Slamf7 immune receptor, which is naturally expressed by the murine multiple myeloma cell line MPC-11, we have developed a syngeneic mouse model for direct comparison of three immunotherapies: monoclonal antibodies (mAb), bispecific T cell engagers (BiTE), and CAR T cells (CART), all targeting Slamf7. Slamf7-BiTE is a bispecific single-chain antibody consisting of α-Slamf7 and α-CD3 Fv fragments joined through a Gly-Ser linker, and Slamf7-CART comprises the α-Slamf7 Fv fragment fused to the msCD8α transmembrane and msCD28, 4-1BB and CD3ζ intracellular signaling domains...
January 10, 2024: Blood Advances
https://read.qxmd.com/read/38195323/soho-state-of-the-art-updates-and-next-questions-next-questions-acute-lymphoblastic-leukemia
#20
REVIEW
Jayastu Senapati, Hagop Kantarjian, Fadi G Haddad, Nicholas J Short, Mary Alma Welch, Nitin Jain, Elias Jabbour
The integration of immune and targeted therapies into the treatment of acute lymphoblastic leukemia (ALL) has significantly improved outcomes, reduced the intensity and duration of chemotherapy, and the reliance on allogeneic stem cell transplantation (SCT). In younger patients with Philadelphia chromosome (Ph)-negative ALL, treatment with Hyper-CVAD and blinatumomab +/- inotuzumab has improved the 3-year overall survival (OS) to above 85%. In older patients, using less intensive chemotherapy (mini-Hyper-CVD) in combination with inotuzumab and blinatumomab has improved the 5-year OS rate to 50%...
January 8, 2024: Clinical Lymphoma, Myeloma & Leukemia
keyword
keyword
13300
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.